Mucopolysaccharidosis (MPS) I is a lysosomal storage disorder characterized by deficient
alpha‐l‐iduronidase activity, leading to abnormal accumulation of glycosaminoglycans …

Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by mutations
in enzymes that degrade glycosaminoglycans (GAG s). Joint disease is present in most …

Mucopolysaccharidosis I is a lysosomal storage disorder characterized by deficient alpha-L-
iduronidase activity, leading to abnormal accumulation of glycosaminoglycans in cells and …

Introduction Musculoskeletal findings in MPS can progress after enzyme replacement. Our
aim was to examine synovial recesses, tendons, retinacula and pulleys using …

Abstract Mucopolysaccharidosis VII (MPS VII) is a lysosomal storage disorder characterized
by a deficiency in β‐glucuronidase activity, leading to systemic accumulation of poorly …

With advances in the treatment of the mucopolysaccharidosis (MPS) disorders,
musculoskeletal problems are increasingly becoming a focus of care for these patients. This …

Progressive skeletal and connective tissue disease represents a significant clinical burden
in all of the mucopolysaccharidoses. Despite the introduction of enzyme replacement …

Mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage diseases caused
by a deficiency of glycosaminoglycan (GAG) catalytic enzymes, resulting in an accumulation …

Degenerative joint disease (DJD) is one aspect of mucopolysaccharidosis VI (MPS VI)
pathology that has proven resistant to systemic enzyme replacement therapy (ERT). In this …

Hunter syndrome or mucopolysaccharidosis type II (MPS-II)(OMIM 309900) is a rare
lysosomal storage disorder caused by deficiency in the activity of the enzyme iduronate-2 …